LLY

Thinking about trading options or stock in Apple, Eli Lilly, General Mills, Activision Blizzard, or Occidental Petroleum?

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, LLY, GIS, ATVI, and OXY.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, LLY, GIS, ATVI, and OXY.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, August 31, 2022

INDIANAPOLIS, Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendthe Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022.Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m., Eastern time.

Key Points: 
  • INDIANAPOLIS, Aug. 31, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendthe Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, Sept. 13, 2022.Anat Ashkenazi, Lilly's senior vice president and chief financial officer, will participate in a fireside chat at 11:10 a.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

DGAP-News: This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems

Retrieved on: 
Thursday, August 25, 2022

Zooming in on the U.S., the American Academy of Dermatology (AAD) reports that 84.5 million Americans 1 in 4 are impacted by skin diseases.

Key Points: 
  • Zooming in on the U.S., the American Academy of Dermatology (AAD) reports that 84.5 million Americans 1 in 4 are impacted by skin diseases.
  • In addition to the debilitating physical and emotional impact, skin diseases can have on people, they can also be a financial strain.
  • Skin diseases cost the U.S. healthcare system $75 billion in medical, preventative and prescription, and nonprescription drug costs.
  • For every three Americans with skin disease, the AAD reports that a dermatologist saw only one.

Lilly to Participate in Citi's 17th Annual BioPharma Conference

Retrieved on: 
Thursday, August 25, 2022

INDIANAPOLIS, Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendCiti's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022.Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:30 p.m., Eastern time.

Key Points: 
  • INDIANAPOLIS, Aug. 25, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attendCiti's 17th Annual BioPharma Conference on Wednesday, Sept. 7, 2022.Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific and medical officer, and president of Lilly Research Laboratories, will participate in a fireside chat at 3:30 p.m., Eastern time.
  • A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay of the presentation will be available on this same website for approximately 90 days.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

DGAP-News: Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated

Retrieved on: 
Friday, August 19, 2022

Americans with diabetes have been relying on insulin injections to manage their illness for decades.

Key Points: 
  • Americans with diabetes have been relying on insulin injections to manage their illness for decades.
  • The U.S. Food and Drug Administration (FDA) recently approved Rybelsus, also known as oral semaglutide, which controls blood sugar in Type 2 diabetes patients.
  • Still, the company claims it is committed to working with health insurance providers and pharmacy benefit managers to increase patient access.
  • This could be a significant milestone towards regulatory clearance and ultimately product commercialization, potentially changing the lives of millions worldwide.

Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for [email protected]

Retrieved on: 
Thursday, August 11, 2022

INDIANAPOLIS, Aug. 11, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for [email protected].

Key Points: 
  • After more than 35 years at Lilly, Stephen Fry, senior vice president, human resources and diversity, will retire at the end of 2022.
  • His depth of knowledge about our business, commitment to Lilly, and expertise in human resources will be missed by employees, management, and our board.
  • Eric Dozier, currently vice president and chief commercial officer for [email protected], is being promoted to succeed Fry as senior vice president, human resources and diversity.
  • There can be no assurance that the leadership changes will achieve Lilly's objectives or that Lilly will execute its strategy as planned.

Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022

INDIANAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.

Key Points: 
  • INDIANAPOLIS, Aug. 4, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will now conduct its second-quarter 2022 financial results investor conference call today at 10 a.m. Eastern time due to third-party technical difficulties.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement

Retrieved on: 
Thursday, July 21, 2022

INDIANAPOLIS, July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.

Key Points: 
  • INDIANAPOLIS, July 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.
  • Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
  • The conference call will begin at 9 a.m. Eastern time.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.

Thinking about trading options or stock in SYSCO Corp, Nike, Eli Lilly, Gitlab, or Atlassian?

Retrieved on: 
Monday, June 27, 2022

NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYY, NKE, LLY, GTLB, and TEAM.

Key Points: 
  • NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYY, NKE, LLY, GTLB, and TEAM.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Retrieved on: 
Tuesday, June 14, 2022

"I am so happy that adults with severe alopecia areata can now take OLUMIANT, a once-daily pill.

Key Points: 
  • "I am so happy that adults with severe alopecia areata can now take OLUMIANT, a once-daily pill.
  • "There is a significant unmet medical need for people with alopecia areata given there has never been an FDA-approved systemic medicine.
  • OLUMIANT's approval is a historic moment, and we're delighted about what it can mean for adults with severe alopecia areata."
  • In these double-blind, placebo-controlled Phase 3 trials, 1,200 patients with severe AA were randomized to receive once-daily OLUMIANT 2-mg, OLUMIANT 4-mg or placebo.